A '''tumor marker''' is a substance found in the [[blood]], [[urine]], or [[Biological tissue|body tissues]] that can be elevated in [[cancer]], among other tissue types. There are many different tumor markers, each indicative of a particular disease process, and they are used in [[oncology]] to help detect the presence of cancer. An elevated level of a tumor marker can indicate cancer; however, there can also be other causes of the elevation.

Tumor markers can be produced directly by the tumor or by non-tumor cells as a response to the presence of a tumor. Most tumor markers are [[tumor antigen]]s, but not all tumor antigens can be used as tumor markers.

==Uses==
Uses of tumor markers can broadly be classified as follows:<ref name="Koepke1992"/>
*''Screening'' for common [[cancer]]s on a population basis. Example: elevated [[prostate specific antigen]] suggests [[prostate cancer]]. 
*''Monitoring'' of [[cancer]] survivors after treatment. Example: elevated [[alpha-fetoprotein|AFP]] in a child previously treated for [[teratoma]] suggests [[relapse]] with [[endodermal sinus tumor]].
*''Diagnosis'' of specific tumor types, particularly in certain [[brain tumor]]s and other instances where [[biopsy]] is not feasible.

As stated in the BMJ 2009, tumour markers should not generally be used for the purpose of diagnosis of cancers, as opposed to monitoring purposes in certain cancers, or in certain cases, screening purposes.<ref>{{cite journal |doi=10.1136/bmj.b3111 |title=Appropriate requesting of serum tumour markers |year=2009 |last1=Kilpatrick |first1=E. S |last2=Lind |first2=M. J |journal=BMJ |volume=339 |pages=b3111 |pmid=19773324}}</ref> The use of these tests without understanding their utility has resulted in inappropriate use of tumour marker blood tests, which has also resulted in further inappropriate over-investigation for cancers.<ref>{{cite journal |doi=10.1136/bmj.325.7370.946 |title=Lesson of the week: Hypothyroidism mimicking intra-abdominal malignancy |year=2002 |last1=Krishnan |first1=S T M |journal=BMJ |volume=325 |issue=7370 |pages=946–7 |pmid=12399347 |last2=Philipose |first2=Z |last3=Rayman |first3=G |pmc=1124444}}</ref>

==Techniques==
Tumor markers can be detected by [[immunohistochemistry]].

If repeated measurements of tumor marker are needed, some clinical testing laboratories provide a special reporting mechanism, a ''serial monitor'', that links test results and other data pertaining to the person being tested. This requires a unique identifier for the person. In the [[United States]] commonly a [[Social Security number]] & Civil Personal Record (CPR) in [[Bahrain]] are used for this. One important function of this mechanism is to ensure that each test is performed using the same assay kit. For example, for [[alpha-fetoprotein|AFP]] many different commercial assay kits, based on different technologies, are available. AFP measurements obtained using different assay kits are not comparable unless special calculations are performed.

Interlaboratory [[proficiency testing]] for tumor marker tests, and for clinical tests more generally, is an emerging field.<ref name="Koepke1992">{{cite journal |doi=10.1002/1097-0142(19920315)69:6+<1578::AID-CNCR2820691312>3.0.CO;2-K |title=Molecular marker test standardization |year=1992 |last1=Koepke |first1=John A. |journal=Cancer |volume=69 |pages=1578–81 |pmid=1540898 |issue=6 Suppl}}</ref>In the United States, New York state is prominent in advocating such research.<ref>Promoting Safe and Effective Genetic Testing in the United States [http://www.genome.gov/10002403 genome.gov]</ref>

== Examples ==
{|class="wikitable"
! Tumor marker !! Associated tumor types 
|-
| [[Alpha fetoprotein]] (AFP) || [[germ cell tumor]], [[hepatocellular carcinoma]]<ref name=Territo2008>[http://books.google.com/books?id=pobC8zHbWzwC&pg=PA746 Page 746] in: 
Title	Manual of clinical oncology
Spiral manual
Manual of Clinical Oncology
Lippincott Manual Series
Authors	Dennis Albert Casciato, Mary C. Territo
Editors	Dennis Albert Casciato, Mary C. Territo
Contributor	Mary C. Territo
Edition	6, illustrated
Publisher	Lippincott Williams & Wilkins, 2008
ISBN 0-7817-6884-5, ISBN 978-0-7817-6884-9 </ref>
|-
| [[CA15-3]] || [[breast cancer]]<ref>{{cite journal |doi=10.1093/annonc/mdl492 |title=CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: A combined analysis of seven International Breast Cancer Study Group trials |year=2006 |last1=Keshaviah |first1=A |last2=Dellapasqua |first2=S |last3=Rotmensz |first3=N |last4=Lindtner |first4=J |last5=Crivellari |first5=D |last6=Collins |first6=J |last7=Colleoni |first7=M |last8=Thurlimann |first8=B |last9=Mendiola |first9=C |journal=Annals of Oncology |volume=18 |issue=4 |pages=701–8 |pmid=17237474}}</ref>
|-
| [[Ca_27-29|CA27-29]] || [[breast cancer]]
|-
| [[CA19-9]] || Mainly [[pancreatic cancer]], but also [[colorectal cancer]] and other types of [[gastrointestinal cancer]].<ref>[https://gpnotebook.co.uk/simplepage.cfm?ID=-80412627 gpnotebook.co.uk > ca-19-9] Retrieved November 2011</ref>
|-
| [[CA-125]] || Mainly [[ovarian cancer]],<ref name="pmid18990955">{{cite journal | author = Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R | title = Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre | journal = Ir Med J | volume = 101 | issue = 8 | pages = 245–7 | year = 2008 | month = September | pmid = 18990955 | doi = | url = | issn = }}</ref> but may also be elevated in for example [[endometrial cancer]], [[fallopian tube cancer]], [[lung cancer]], [[breast cancer]] and [[gastrointestinal cancer]].<ref name="pmid10228898">{{cite journal | author = Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB | title = CA 125: the past and the future | journal = Int. J. Biol. Markers | volume = 13 | issue = 4 | pages = 179–87 | year = 1998 | pmid = 10228898 | doi = | url = | issn = }}</ref> May also increase in [[endometriosis]].<ref name="pmid17804443">{{cite journal | author = Bagan P, Berna P, Assouad J, Hupertan V, Le Pimpec Barthes F, Riquet M | title = Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax | journal = Eur. Respir. J. | volume = 31 | issue = 1 | pages = 140–2 | year = 2008 | month = January | pmid = 17804443 | doi = 10.1183/09031936.00094206 | url =  }}</ref>
|-
| [[Calretinin]] || [[mesothelioma]], [[sex cord-gonadal stromal tumour]], [[adrenocortical carcinoma]], [[synovial sarcoma]]<ref name=Territo2008/>
|-
| [[Carcinoembryonic antigen]] || [[gastrointestinal cancer]], [[cervix cancer]], [[lung cancer]], [[ovarian cancer]], [[breast cancer]], [[urinary tract cancer]]<ref name=Territo2008/>
|-
| [[CD34]] || [[hemangiopericytoma]]/[[solitary fibrous tumor]], [[pleomorphic lipoma]], [[gastrointestinal stromal tumor]], [[dermatofibrosarcoma protuberans]]<ref name=Territo2008/>
|-
| [[CD99]] || [[Ewing sarcoma]], [[primitive neuroectodermal tumor]], [[hemangiopericytoma]]/[[solitary fibrous tumor]], [[synovial sarcoma]], [[lymphoma]], [[leukemia]], [[sex cord-gonadal stromal tumour]]<ref name=Territo2008/>
|-
| [[CD117]] || [[gastrointestinal stromal tumor]], [[mastocytosis]], [[seminoma]]<ref name=Territo2008/>
|-
| [[Chromogranin]] || [[neuroendocrine tumor]]<ref name=Territo2008/>
|-
| [[Cytokeratin]] (various types) || Many types of [[carcinoma]], some types of [[sarcoma]]<ref name=Territo2008/>
|-
| [[Desmin]] || [[smooth muscle sarcoma]], [[skeletal muscle sarcoma]], [[endometrial stromal sarcoma]]<ref name=Territo2008/>
|-
| [[Epithelial membrane protein]] (EMA) || many types of [[carcinoma]], [[meningioma]], some types of [[sarcoma]]<ref name=Territo2008/>
|-
| [[Factor VIII]], [[CD31]] [[FL1]] || [[vascular sarcoma]]<ref name=Territo2008/>
|-
| [[Glial fibrillary acidic protein ]] (GFAP) || [[glioma]] ([[astrocytoma]], [[ependymoma]])<ref name=Territo2008/>
|-
| [[Gross cystic disease fluid protein]] (GCDFP-15) || [[breast cancer]], [[ovarian cancer]], [[salivary gland cancer]]<ref name=Territo2008/>
|-
| [[HMB-45]] || [[melanoma]], [[PEComa]] (for example [[angiomyolipoma]]), [[clear cell adenocarcinoma|clear cell carcinoma]], [[adrenocortical carcinoma]]<ref name=Territo2008/>
|-
| [[Human chorionic gonadotropin]] (hCG) || [[gestational trophoblastic disease]], [[germ cell tumor]], [[choriocarcinoma]]<ref name=Territo2008/>
|-
| [[immunoglobulin]] || [[lymphoma]], [[leukemia]]<ref name=Territo2008/>
|-
| [[inhibin]] || [[sex cord-gonadal stromal tumour]], [[adrenocortical carcinoma]], [[hemangioblastoma]]<ref name=Territo2008/>
|-
| [[keratin]] (various types) || [[carcinoma]], some types of [[sarcoma]]<ref name=Territo2008/>
|-
| [[PTPRC]] (CD45) || [[lymphoma]], [[leukemia]], [[histiocytic tumor]]<ref name=Territo2008/>
|-
| [[lymphocyte marker]] (various types || [[lymphoma]], [[leukemia]]<ref name=Territo2008/>
|-
| [[MART-1]] (Melan-A) || [[melanoma]], steroid-producing tumors ([[adrenocortical carcinoma]], [[gonadal tumor]])<ref name=Territo2008/>
|-
| [[Myo D1]] || [[rhabdomyosarcoma]], [[small, round, blue cell tumour]]<ref name=Territo2008/>
|-
| [[muscle-specific actin]] (MSA) || [[myosarcoma]] ([[leiomyosarcoma]], [[rhabdomyosarcoma]])<ref name=Territo2008/>
|-
| [[neurofilament]] || [[neuroendocrine tumor]], [[small-cell carcinoma]] of the lung<ref name=Territo2008/>
|-
| [[neuron-specific enolase]] (NSE) || [[neuroendocrine tumor]], [[small-cell carcinoma]] of the lung, [[breast cancer]]<ref name=Territo2008/>
|-
| [[placental alkaline phosphatase]] (PLAP) || [[seminoma]], [[dysgerminoma]], [[embryonal carcinoma]]<ref name=Territo2008/>
|-
| [[prostate-specific antigen]] || [[prostate]]<ref name=Territo2008/>
|-
| [[S100 protein]] || [[melanoma]], [[sarcoma]] ([[neurosarcoma]], [[lipoma]], [[chondrosarcoma]]), [[astrocytoma]], [[gastrointestinal stromal tumor]], [[salivary gland cancer]], some types of [[adenocarcinoma]], [[histiocytic tumor]] ([[dendritic cell]], [[macrophage]])<ref name=Territo2008/>
|-
| [[smooth muscle actin]] (SMA) || [[gastrointestinal stromal tumor]], [[leiomyosarcoma]], [[PEComa]]<ref name=Territo2008/>
|-
| [[synaptophysin]] || [[neuroendocrine tumor]]<ref name=Territo2008/>
|-
| [[thyroglobulin]] || [[thyroid cancer]] (but not in [[medullary thyroid cancer]])<ref name=Territo2008/>
|-
| [[thyroid transcription factor-1]] || all types of [[thyroid cancer]], [[lung cancer]]<ref name=Territo2008/>
|-
| [[Tumor M2-PK]]  || [[colorectal cancer]],<ref name=Haug2007>{{cite journal |doi=10.1038/sj.bjc.6603712 |title=Tumour M2-PK as a stool marker for colorectal cancer: Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients |year=2007 |last1=Haug |first1=U |last2=Rothenbacher |first2=D |last3=Wente |first3=M N |last4=Seiler |first4=C M |last5=Stegmaier |first5=C |last6=Brenner |first6=H |journal=British Journal of Cancer}}</ref> [[Breast cancer]],<ref>{{cite journal |pmid=11326672 |year=2000 |last1=Lüftner |first1=D |last2=Mesterharm |first2=J |last3=Akrivakis |first3=C |last4=Geppert |first4=R |last5=Petrides |first5=PE |last6=Wernecke |first6=KD |last7=Possinger |first7=K |title=Tumor type M2 pyruvate kinase expression in advanced breast cancer |volume=20 |issue=6D |pages=5077–82 |journal=Anticancer research}}</ref><ref>{{cite journal |pmid=20592362 |year=2010 |last1=Benesch |first1=C |last2=Schneider |first2=C |last3=Voelker |first3=HU |last4=Kapp |first4=M |last5=Caffier |first5=H |last6=Krockenberger |first6=M |last7=Dietl |first7=J |last8=Kammerer |first8=U |last9=Schmidt |first9=M |title=The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer |volume=30 |issue=5 |pages=1689–94 |journal=Anticancer research}}</ref> [[renal cell carcinoma]]<ref>{{cite journal |pmid=11326675 |year=2000 |last1=Oremek |first1=GM |last2=Sapoutzis |first2=N |last3=Kramer |first3=W |last4=Bickeböller |first4=R |last5=Jonas |first5=D |title=Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma |volume=20 |issue=6D |pages=5095–8 |journal=Anticancer research}}</ref><ref>{{cite journal |pmid=10470199 |year=1999 |last1=Wechsel |first1=HW |last2=Petri |first2=E |last3=Bichler |first3=KH |last4=Feil |first4=G |title=Marker for renal cell carcinoma (RCC): The dimeric form of pyruvate kinase type M2 (Tu M2-PK) |volume=19 |issue=4A |pages=2583–90 |journal=Anticancer research}}</ref> [[Lung cancer]],<ref>{{cite journal |pmid=12624710 |year=2003 |last1=Schneider |first1=J |last2=Peltri |first2=G |last3=Bitterlich |first3=N |last4=Philipp |first4=M |last5=Velcovsky |first5=HG |last6=Morr |first6=H |last7=Katz |first7=N |last8=Eigenbrodt |first8=E |title=Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients |volume=2 |issue=4 |pages=185–91 |doi=10.1007/s102380300005 |journal=Clinical and experimental medicine}}</ref><ref>{{cite journal |pmid=17882813 |year=2007 |last1=Oremek |first1=G |last2=Kukshaĭte |first2=R |last3=Sapoutzis |first3=N |last4=Ziolkovski |first4=P |title=The significance of TU M2-PK tumor marker for lung cancer diagnostics |volume=85 |issue=7 |pages=56–8 |journal=Klinicheskaia meditsina}}</ref> [[Pancreatic cancer]],<ref>{{cite journal |pmid=11326648 |year=2000 |last1=Hardt |first1=PD |last2=Ngoumou |first2=BK |last3=Rupp |first3=J |last4=Schnell-Kretschmer |first4=H |last5=Kloer |first5=HU |title=Tumor M2-pyruvate kinase: A promising tumor marker in the diagnosis of gastro-intestinal cancer |volume=20 |issue=6D |pages=4965–8 |journal=Anticancer research}}</ref> [[Esophageal Cancer]],<ref name="DoiMEGbef">{{cite journal |doi=10.1097/MEG.0b013e3280102f78 |title=Tumour M2-pyruvate kinase: A gastrointestinal cancer marker |year=2007 |last1=Kumar |first1=Yogesh |last2=Tapuria |first2=Niteen |last3=Kirmani |first3=Naveed |last4=Davidson |first4=Brian R. |journal=European Journal of Gastroenterology & Hepatology |volume=19 |issue=3 |pages=265}}</ref> [[Stomach Cancer]],<ref name="DoiMEGbef" />[[Cervical Cancer]],<ref>{{cite journal |pmid=15210041 |year=2004 |last1=Kaura |first1=B |last2=Bagga |first2=R |last3=Patel |first3=FD |title=Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma |volume=30 |issue=3 |pages=193–6 |doi=10.1111/j.1447-0756.2004.00187.x |journal=The journal of obstetrics and gynaecology research}}</ref> [[Ovarian Cancer]],<ref>{{cite journal |pmid=17479666 |year=2007 |last1=Ahmed |first1=AS |last2=Dew |first2=T |last3=Lawton |first3=FG |last4=Papadopoulos |first4=AJ |last5=Devaja |first5=O |last6=Raju |first6=KS |last7=Sherwood |first7=RA |title=M2-PK as a novel marker in ovarian cancer. A prospective cohort study |volume=28 |issue=2 |pages=83–8 |journal=European journal of gynaecological oncology}}</ref>
|-
| [[vimentin]] || [[sarcoma]], [[renal cell carcinoma]], [[endometrial cancer]], [[lung carcinoma]], [[lymphoma]], [[leukemia]], [[melanoma]]<ref name=Territo2008/>
|}

==Sources of inaccuracy==
The [[high dose hook effect]] is an artefact of tumor marker immunoassay kits, that causes the reported quantity of tumor marker to be incorrectly low when the quantity is high. An undetected hook effect may cause delayed recognition of a tumor.<ref name="pmid16278263">{{cite journal |doi=10.1210/jc.2005-1429 |title="Hook Effect" in Calcitonin Immunoradiometric Assay in Patients with Metastatic Medullary Thyroid Carcinoma: Case Report and Review of the Literature |year=2005 |last1=Leboeuf |first1=R. |journal=Journal of Clinical Endocrinology & Metabolism |volume=91 |issue=2 |pages=361}}</ref> The hook effect can be detected by analyzing serial dilutions. The hook effect is absent if the reported quantities of tumor marker in a serial dilution are proportional to the dilution.

== See also ==
* [[Tumor antigen]]
* [[List of cancer types]]

==References==
{{reflist|2}}

==Further reading==
*{{cite journal |pmid=11326672 |year=2000 |last1=Lüftner |first1=D |last2=Mesterharm |first2=J |last3=Akrivakis |first3=C |last4=Geppert |first4=R |last5=Petrides |first5=PE |last6=Wernecke |first6=KD |last7=Possinger |first7=K |title=Tumor type M2 pyruvate kinase expression in advanced breast cancer |volume=20 |issue=6D |pages=5077–82 |journal=Anticancer research}}

==External links==
* {{MeshName|Tumor+Markers,+Biological}}

{{Tumor markers}}
{{Blood tests}}
[[Category:Tumor markers|*]]